News

UK endows £250m to life sciences
Enlarge image

FundingUK

UK endows £250m to life sciences

25.05.2012 - With the aim to maintain its status one of the global leading life sciences nations, the UK has set up a large funding initiative.

London – Minister for Universities and Science, David Willetts, announced that £250M has been allocated for the first phase of several five year strategic investment programmes. This includes 26 strategic science programmes and 14 key national research capabilities, to be delivered by eight of the UK's world-leading bioscience research institutes and their university partners. The process will be led by Britain's Biotechnology and Biological Sciences Research Council (BBSRC). 

Commenting on the funding, Willetts said: "This investment will sustain excellent science at some of the UK's leading institutes and universities. This will drive growth, support highly skilled jobs and keep the UK at the very forefront of bioscience, with benefits ranging from healthcare to energy and global food security." The plan is thought to help the UK to meet challenges such as sustainably feeding the growing world population, finding alternatives to dwindling fossil fuels and supporting an ageing society to remain healthy for longer.  

The Minister made the announcement in a speech during a visit at the Babraham Research Campus. The campus, a BBSRC National Research and Innovation Campus, is one of the privileged institutes and will receive £37M. Others are the Institute of Biological, Environmental and Rural Sciences, Aberystwyth University (£13M), the Genome Analysis Centre in Norwich (£19M), the Roslin Institute at the University of Edinburgh (£23M), the Institute for Animal Health in Pirbright (£38M), the Institute of Food Research in Norwich (£29M), the John Innes Centre in Norwich (£42M) and the Rothamsted Research in Harpenden (£41M).

The initiative complements a funding programme aimed to boost translational medicine, that was announced in April.

http://www.european-biotechnology-news.com/news/news/2012-02/uk-endows-pound250m-to-life-sciences.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%

FLOP

  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015